Literature DB >> 25765239

Tissue and species differences in the glucuronidation of glabridin with UDP-glucuronosyltransferases.

Bin Guo1, Zhongze Fang2, Lu Yang3, Ling Xiao4, Yangliu Xia5, Frank J Gonzalez6, Liangliang Zhu7, Yunfeng Cao8, Guangbo Ge5, Ling Yang5, Hongzhi Sun9.   

Abstract

Glabridin (GA) has gained wide application in the cosmetics and food industry. This study was performed to investigate its metabolic inactivation and elimination by glucuronidation by use of liver and intestine microsomes from humans (HLM and HIM) and rats (RLM and RIM), and liver microsomes from cynomolgus monkeys and beagle dogs (CyLM and DLM). Both hydroxyl groups at the C2 and C4 positions of the B ring are conjugated to generate two mono-glucuronides (M1 and M2). HIM, RIM and RLM showed the most robust activity in catalyzing M2 formation with intrinsic clearance values (Clint) above 2000 μL/min/mg, with little measurable M1 formation activity. DLM displayed considerable activity both in M1 and M2 formation, with Clint values of 71 and 214 μL/min/mg, respectively, while HLM and CyLM exhibited low activities in catalyzing M1 and M2 formation, with Clint values all below 20 μL/min/mg. It is revealed that UGT1A1, 1A3, 1A9, 2B7, 2B15 and extrahepatic UGT1A8 and 1A10 are involved in GA glucuronidation. Nearly all UGTs preferred M2 formation except for UGT1A1. Notably, UGT1A8 displayed the highest activity with a Clint value more than 5-fold higher than the other isoforms. Chemical inhibition studies, using selective inhibitors of UGT1A1, 1A9, 2B7 and 1A8, further revealed that UGT1A8 contributed significantly to intestinal GA glucuronidation in humans. In summary, this in vitro study demonstrated large species differences in GA glucuronidation by liver and intestinal microsomes, and that intestinal UGTs are important for the pathway in humans.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Glabridin; Glucuronidation; Species differences; UDP-glucuronosyltransferases

Mesh:

Substances:

Year:  2015        PMID: 25765239      PMCID: PMC6300978          DOI: 10.1016/j.cbi.2015.03.001

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  4 in total

1.  The repressive effect of miR-148a on Wnt/β-catenin signaling involved in Glabridin-induced anti-angiogenesis in human breast cancer cells.

Authors:  Juan Mu; Dongmei Zhu; Zhaoxia Shen; Shilong Ning; Yun Liu; Juan Chen; Yuan Li; Zhong Li
Journal:  BMC Cancer       Date:  2017-05-02       Impact factor: 4.430

2.  Species Differences in Stereoselective Pharmacokinetics of HSG4112, A New Anti-Obesity Agent.

Authors:  In Yong Bae; Min Sun Choi; Young Seok Ji; Sang-Ku Yoo; Kyungil Kim; Hye Hyun Yoo
Journal:  Pharmaceutics       Date:  2020-02-03       Impact factor: 6.321

3.  Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity.

Authors:  Leo Sungwong Choi; In Geun Jo; Ku Suk Kang; Jeong Ho Im; Jiyoung Kim; Jinyoung Kim; Jin Wook Chung; Sang-Ku Yoo
Journal:  Int J Obes (Lond)       Date:  2020-09-17       Impact factor: 5.095

4.  In vitro differences in toddalolactone metabolism in various species and its effect on cytochrome P450 expression.

Authors:  Lina Shan; Xianbao Shi; Tingting Hu; Jiayin Hu; Zhe Guo; Yonggui Song; Dan Su; Xiaoyong Zhang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.